As scientists we have learned that neurodegenerative disorders need a new form of treatment, as the existing treatments have a higher rate of failure. For the past 20 years we have had a different notion on neurodegenerative disorders, it's time to rethink the way we treat them and to innovate in this area, that is why we want to bring new forms of treatment to the society.
We want to help improve and democratize mental health treatments
This is why we founded Actipulse Neuroscience®

We are a neuro-tech company specialized in the research and engineering of Non-Invasive Brain Stimulation technologies for the treatment of psychiatric and neurological disorders.

We are pioneers in Non-Invasive Brain Stimulation technologies with a particular focus on transcranial neuromodulation devices using high frequency magnetic pulses that target multiple well known, but neglected pathogenic mechanisms in neurodegenerative disorders.

Current Clinical Pipeline

Actipulse Neuroscience is focused on leading world class research with a particular emphasis on respecting the highest clinical and ethical standards.

  • Major Depressive Disorder

    PIVOTAL STUDY =n240

  • Tobacco Addiction

    PILOT STUDY = n50

  • Alzheimer’s Disease

    PILOT STUDY = n30

  • CNC2

    PLANNED

  • CNC3

    PLANNED

  • CNC4

    PLANNED

    Anticipated start of next milestone: Q1 and Q4 2022

The future golden standard of neurodegenerative treatment

Actipulse Neuroscience has for goal to be the golden standard of neuromodulation technologies in the next five years and to become an integral part of the treatment of the millions of patients suffering from neurological and psychiatric disorders and dementia in the world.

Contact us
Our investors

For Investor Relations inquiries

Please email:
adrien.chatillon(at)actipulse.com


Actipulse Neuroscience, Inc.

Global Headquarters
210 Broadway,
Cambridge, MA